MedTech Acquisition Corporation announced the pricing of its upsized $220 million IPO this evening and its units are expected to begin trading on the Nasdaq under the symbol “MTACU” tomorrow, Friday, December 18.
The new company aims to combine with a US healthcare business that uses innovations such as robotics in surgery, patient therapies or drug delivery. MedTech is led by Chairman Karim Karti, CEO alongside Director Christopher C. Dewey, CFO and Director David J. Matlin and Chief Administrative Officer and Secretary Robert H. Weiss.
Total SPAC deal count for 2020 year-to-date is now 241 with $80.8 billion in gross proceeds raised. This offering is expected to close on Tuesday, December 22.
Raymond James & Associates, Inc. is acting as sole book running manager for the offering. Ellenoff Grossman & Schole LLP is serving as Issuer’s Counsel with Greenberg Traurig LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Stock Transfer & Trust Company LLC is acting as trustee.